Is CBLL or PLSE more profitable?

CeriBell has a net margin of -64.73% compared to Pulse Biosciences' net margin of -6,755.78%. CeriBell's return on equity of -44.85% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -64.73% -44.85% -35.69% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media refer more to CBLL or PLSE?

In the previous week, CeriBell had 22 more articles in the media than Pulse Biosciences. MarketBeat recorded 26 mentions for CeriBell and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.61 beat CeriBell's score of 0.52 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, TMDX or CBLL?

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 5.26 $190.29M $3.89 23.71 CeriBell $101.96M 8.83 -$53.41M -$1.76 N/A

Does the media prefer TMDX or CBLL?

In the previous week, CeriBell had 16 more articles in the media than TransMedics Group. MarketBeat recorded 26 mentions for CeriBell and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.99 beat CeriBell's score of 0.52 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CeriBell 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, CBLL or AXGN?

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $101.96M 8.83 -$53.41M -$1.76 N/A AxoGen $251.17M 11.04 -$15.70M -$0.68 N/A

Is CBLL or AXGN more profitable?

AxoGen has a net margin of -13.36% compared to CeriBell's net margin of -64.73%. AxoGen's return on equity of -8.90% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -64.73% -44.85% -35.69% AxoGen -13.36% -8.90% -6.47%

Does the media refer more to CBLL or AXGN?

In the previous week, CeriBell had 17 more articles in the media than AxoGen. MarketBeat recorded 26 mentions for CeriBell and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.66 beat CeriBell's score of 0.52 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, CBLL or ATRC?

AtriCure has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $101.96M 8.83 -$53.41M -$1.76 N/A AtriCure $534.53M 4.58 -$11.45M $0.21 229.33

Is CBLL or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to CeriBell's net margin of -64.73%. AtriCure's return on equity of 2.34% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -64.73% -44.85% -35.69% AtriCure 1.85% 2.34% 1.77%

Does the media favor CBLL or ATRC?

In the previous week, CeriBell had 9 more articles in the media than AtriCure. MarketBeat recorded 26 mentions for CeriBell and 17 mentions for AtriCure. AtriCure's average media sentiment score of 0.77 beat CeriBell's score of 0.52 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 7 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CBLL or BFLY?

In the previous week, CeriBell had 20 more articles in the media than Butterfly Network. MarketBeat recorded 26 mentions for CeriBell and 6 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 1.11 beat CeriBell's score of 0.52 indicating that Butterfly Network is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CeriBell (CBLL) Competitors

$23.45 -0.50 (-2.09%)

As of 04:00 PM Eastern

Compare

CBLL vs. PLSE, TMDX, AXGN, ATRC, and BFLY

Should you buy CeriBell stock or one of its competitors? CeriBell's main competitors and comparable companies include Pulse Biosciences (PLSE), TransMedics Group (TMDX), AxoGen (AXGN), AtriCure (ATRC), and Butterfly Network (BFLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does CeriBell compare to Pulse Biosciences?

CeriBell (NASDAQ:CBLL) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

76.9% of Pulse Biosciences shares are owned by institutional investors. 17.7% of CeriBell shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CeriBell has a net margin of -64.73% compared to Pulse Biosciences' net margin of -6,755.78%. CeriBell's return on equity of -44.85% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

In the previous week, CeriBell had 22 more articles in the media than Pulse Biosciences. MarketBeat recorded 26 mentions for CeriBell and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.61 beat CeriBell's score of 0.52 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$101.96M	8.83	-$53.41M	-$1.76	N/A
Pulse Biosciences	$1.19M	2,809.28	-$72.78M	-$1.18	N/A

CeriBell has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

CeriBell presently has a consensus price target of $22.40, suggesting a potential downside of 4.48%. Pulse Biosciences has a consensus price target of $45.25, suggesting a potential downside of 5.93%. Given CeriBell's stronger consensus rating and higher possible upside, analysts plainly believe CeriBell is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

CeriBell beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does CeriBell compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and CeriBell (NASDAQ:CBLL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

TransMedics Group presently has a consensus target price of $124.18, suggesting a potential upside of 34.66%. CeriBell has a consensus target price of $22.40, suggesting a potential downside of 4.48%. Given TransMedics Group's higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

TransMedics Group has a net margin of 22.69% compared to CeriBell's net margin of -64.73%. TransMedics Group's return on equity of 15.88% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
CeriBell	-64.73%	-44.85%	-35.69%

In the previous week, CeriBell had 16 more articles in the media than TransMedics Group. MarketBeat recorded 26 mentions for CeriBell and 10 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.99 beat CeriBell's score of 0.52 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CeriBell	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	5.26	$190.29M	$3.89	23.71
CeriBell	$101.96M	8.83	-$53.41M	-$1.76	N/A

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 17.7% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

TransMedics Group has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Summary

TransMedics Group beats CeriBell on 12 of the 17 factors compared between the two stocks.

How does CeriBell compare to AxoGen?

CeriBell (NASDAQ:CBLL) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

80.3% of AxoGen shares are held by institutional investors. 17.7% of CeriBell shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CeriBell presently has a consensus price target of $22.40, suggesting a potential downside of 4.48%. AxoGen has a consensus price target of $51.56, suggesting a potential downside of 0.05%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, CeriBell had 17 more articles in the media than AxoGen. MarketBeat recorded 26 mentions for CeriBell and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.66 beat CeriBell's score of 0.52 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

AxoGen has a net margin of -13.36% compared to CeriBell's net margin of -64.73%. AxoGen's return on equity of -8.90% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
AxoGen	-13.36%	-8.90%	-6.47%

CeriBell has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$101.96M	8.83	-$53.41M	-$1.76	N/A
AxoGen	$251.17M	11.04	-$15.70M	-$0.68	N/A

Summary

AxoGen beats CeriBell on 13 of the 17 factors compared between the two stocks.

How does CeriBell compare to AtriCure?

CeriBell (NASDAQ:CBLL) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

CeriBell presently has a consensus target price of $22.40, indicating a potential downside of 4.48%. AtriCure has a consensus target price of $48.63, indicating a potential upside of 0.97%. Given AtriCure's stronger consensus rating and higher probable upside, analysts clearly believe AtriCure is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

CeriBell has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

In the previous week, CeriBell had 9 more articles in the media than AtriCure. MarketBeat recorded 26 mentions for CeriBell and 17 mentions for AtriCure. AtriCure's average media sentiment score of 0.77 beat CeriBell's score of 0.52 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	7 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a net margin of 1.85% compared to CeriBell's net margin of -64.73%. AtriCure's return on equity of 2.34% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
AtriCure	1.85%	2.34%	1.77%

99.1% of AtriCure shares are held by institutional investors. 17.7% of CeriBell shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AtriCure has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$101.96M	8.83	-$53.41M	-$1.76	N/A
AtriCure	$534.53M	4.58	-$11.45M	$0.21	229.33

Summary

AtriCure beats CeriBell on 13 of the 16 factors compared between the two stocks.

How does CeriBell compare to Butterfly Network?

CeriBell (NASDAQ:CBLL) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

CeriBell has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

CeriBell has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$101.96M	8.83	-$53.41M	-$1.76	N/A
Butterfly Network	$97.61M	23.79	-$77.06M	-$0.29	N/A

In the previous week, CeriBell had 20 more articles in the media than Butterfly Network. MarketBeat recorded 26 mentions for CeriBell and 6 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 1.11 beat CeriBell's score of 0.52 indicating that Butterfly Network is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell has a net margin of -64.73% compared to Butterfly Network's net margin of -66.74%. Butterfly Network's return on equity of -33.99% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
Butterfly Network	-66.74%	-33.99%	-22.96%

37.9% of Butterfly Network shares are owned by institutional investors. 17.7% of CeriBell shares are owned by company insiders. Comparatively, 22.0% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CeriBell currently has a consensus target price of $22.40, indicating a potential downside of 4.48%. Butterfly Network has a consensus target price of $5.56, indicating a potential downside of 36.21%. Given CeriBell's stronger consensus rating and higher probable upside, research analysts clearly believe CeriBell is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

CeriBell beats Butterfly Network on 9 of the 17 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$899.96M	$5.79B	$7.29B	$12.77B
Dividend Yield	N/A	1.74%	2.53%	10.79%
P/E Ratio	-13.32	26.01	272.49	24.14
Price / Sales	8.83	44.53	626.72	98.16
Price / Cash	N/A	33.27	78.57	53.12
Price / Book	7.02	6.24	13.14	6.23
Net Income	-$53.41M	$149.10M	$3.47B	$348.07M
7 Day Performance	-5.79%	0.53%	1.38%	0.67%
1 Month Performance	38.68%	9.26%	8.62%	4.84%
1 Year Performance	104.62%	6.82%	25.90%	16.83%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	1.3058 of 5 stars	$23.45 -2.1%	$22.40 -4.5%	+109.4%	$899.96M	$101.96M	N/A	N/A	Trending News Insider Trade
PLSE Pulse Biosciences	1.5151 of 5 stars	$47.93 -2.4%	$45.25 -5.6%	+197.1%	$3.31B	$350K	N/A	140
TMDX TransMedics Group	4.4081 of 5 stars	$93.01 -0.6%	$124.18 +33.5%	-18.6%	$3.21B	$605.49M	23.89	210
AXGN AxoGen	2.0987 of 5 stars	$49.76 +1.1%	$51.00 +2.5%	+237.6%	$2.67B	$225.21M	N/A	450	Positive News Analyst Forecast
ATRC AtriCure	2.6766 of 5 stars	$48.46 -1.7%	$48.63 +0.3%	+28.6%	$2.47B	$569.62M	230.94	1,300	News Coverage Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. PLSE, TMDX, AXGN, ATRC, and BFLY

How does CeriBell compare to Pulse Biosciences?

Summary

How does CeriBell compare to TransMedics Group?

Summary

How does CeriBell compare to AxoGen?

Summary

How does CeriBell compare to AtriCure?

Summary

How does CeriBell compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. PLSE, TMDX, AXGN, ATRC, and BFLY

How does CeriBell compare to Pulse Biosciences?

Do institutionals & insiders hold more shares of CBLL or PLSE?

Is CBLL or PLSE more profitable?

Does the media refer more to CBLL or PLSE?

Which has stronger valuation & earnings, CBLL or PLSE?

Which has more risk & volatility, CBLL or PLSE?

Do analysts rate CBLL or PLSE?

Summary

How does CeriBell compare to TransMedics Group?

Do analysts prefer TMDX or CBLL?

Is TMDX or CBLL more profitable?

Does the media prefer TMDX or CBLL?

Which has higher earnings & valuation, TMDX or CBLL?

Do institutionals and insiders hold more shares of TMDX or CBLL?

Which has more volatility and risk, TMDX or CBLL?

Summary

How does CeriBell compare to AxoGen?

Do insiders & institutionals have more ownership in CBLL or AXGN?

Do analysts recommend CBLL or AXGN?

Does the media refer more to CBLL or AXGN?

Is CBLL or AXGN more profitable?

Which has more risk & volatility, CBLL or AXGN?

Which has higher earnings & valuation, CBLL or AXGN?

Summary

How does CeriBell compare to AtriCure?

Do analysts rate CBLL or ATRC?

Which has more volatility & risk, CBLL or ATRC?

Does the media favor CBLL or ATRC?

Is CBLL or ATRC more profitable?

Do institutionals & insiders hold more shares of CBLL or ATRC?

Which has preferable valuation & earnings, CBLL or ATRC?

Summary

How does CeriBell compare to Butterfly Network?

Which has more volatility & risk, CBLL or BFLY?

Which has higher earnings & valuation, CBLL or BFLY?

Does the media refer more to CBLL or BFLY?

Is CBLL or BFLY more profitable?

Do insiders & institutionals hold more shares of CBLL or BFLY?

Do analysts rate CBLL or BFLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools